Piroxicam olamine  (Synonyms: CP-16171 olamine)

Piroxicam olamine (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC₅₀s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively^[1].

IC50: 47 μM (COX-1, in human monocytes), 25 μM (COX-2, human monocytes)^[1]

Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC₅₀s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively^[1]. Piroxicam (CP-16171) (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (CP-16171) (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Piroxicam (CP-16171) (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

392.43

C₁₇H₂₀N₄O₅S

85056-47-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kato M, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001 Dec;53(12):1679-85.  [Content Brief]

  [2]. Mohammed SI, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002 Jan 15;62(2):356-8.  [Content Brief]

  [3]. Silva J, et al. Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. Anticancer Res. 2017 Apr;37(4):1737-1745.  [Content Brief]